Long-Term Safety and Efficacy of Donepezil in Patients with Dementia with Lewy Bodies: Results from a 52-Week, Open-Label, Multicenter Extension Study | Zendy

Manabu Ikeda | Zendy; Etsuro Mori | Zendy; Kenji Kosaka | Zendy; Eizo Iseki | Zendy; Mamoru Hashimoto | Zendy; Noriyuki Matsukawa | Zendy; Kazutaka Matsuo | Zendy; Masaki Nakagawa | Zendy; Donepezil-DLB Study Investigators | Zendy

Open Access

Long-Term Safety and Efficacy of Donepezil in Patients with Dementia with Lewy Bodies: Results from a 52-Week, Open-Label, Multicenter Extension Study

Author(s) -

Manabu Ikeda,

Etsuro Mori,

Kenji Kosaka,

Eizo Iseki,

Mamoru Hashimoto,

Noriyuki Matsukawa,

Kazutaka Matsuo,

Masaki Nakagawa,

Donepezil-DLB Study Investigators

Publication year - 2013

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000351672

Subject(s) - donepezil , dementia , placebo , medicine , adverse effect , randomized controlled trial , psychology , dementia with lewy bodies , incidence (geometry) , cognitive decline , pediatrics , physics , alternative medicine , disease , pathology , optics

To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research